Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 46 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: standard nebulizer Clear all

Conditions: COPD
Interventions: Ensifentrine 3 mg twice daily; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive, COPD
Interventions: Ensifentrine, Placebo, LABA/LAMA; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Ensifentrine, Placebo, Standard of Care (SOC); Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Hialeah Gardens, Florida • Loxahatchee Groves, Florida • Valparaiso, Indiana + 4 more

Conditions: Asthma
Interventions: Intervention: Budesonide, Usual care: albuterol + systemic steroids; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
Interventions: Cisplatin, Doxorubicin; Drug
Lead sponsor: Odense University Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Status Asthmaticus
Interventions: Helium-oxygen-driven albuterol nebulizer, Oxygen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 24 Months to 18 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Adenocarcinoma Pancreas
Interventions: PIPAC, Nab-paclitaxel; Device · Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: PTSD, Smoking
Interventions: Bupropion, nicotine replacement therapy, Smoking cessation counseling, mobile contingency management, Stay Quit Coach; Drug · Other · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia, Cigarette Smoking
Interventions: Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypoxemic Respiratory Failure, Airway Obstruction
Interventions: nebulizer via in-line drug delivery maintaining high-flow nasal cannula oxygen, standard jet nebulization (SJN) with face mask; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Asthma, Pediatric ALL
Interventions: budesonide, beclomethasone; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: Up to 18 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Asthma
Interventions: AccuPAP, Albuterol and Ipratropium Continuous Nebulizer; Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COPD
Interventions: hyperpolarized 129Xe gas MRI, Bevespi Aerosphere; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 40 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: Nebulizer Education Intervention, Standard Asthma Education Groups; Behavioral
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 2 Years to 8 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiovascular Diseases, Dysphagia
Interventions: Fiberoptic Endoscopic Evaluation of Swallowing, Simultaneous FEES and Videofluoroscopy instrumental swallowing exam, Videofluoroscopy instrumental swallowing exam (VFSS), Voluntary Cough Peak Expiratory Flow (PEF) Testing, Reflex Cough Screen, Lingual Pressure Testing, Speech Testing; Diagnostic Test · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Columbus, Ohio

Conditions: Asthma
Interventions: ICS Prescription + Standard Asthma ED Discharge Therapy, Standard Asthma ED Discharge Therapy; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma, Chronic Obstructive Pulmonary Disease
Interventions: standard nebulizer, breath actuated nebulizer; Device
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation); Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 1 more

Conditions: Asthma
Interventions: Budesonide, albuterol, Ipratropium bromide, Prednisone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: East Meadow, New York • Queens, New York • The Bronx, New York

Conditions: Acute Bronchiolitis
Interventions: 3% Hypertonic Saline, 0.9 % normal saline; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Months to 12 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Covid19, Respiratory Failure
Interventions: Nebulised unfractionated heparin (UFH); Drug
Lead sponsor: Australian National University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Chronic Obstructive Pulmonary Disease - COPD
Interventions: Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more

Search by objective public record fields.

Effect of Ensifentrine Treatment on CAT Score

Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)

Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)

Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

In Line Aerosol Nebulization With High Flow

Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge

Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

Nebulizer Intervention for Minority Children With Asthma

Clinical Markers of Dysphagia in Cardiac Surgical Patients

Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma

Breath Actuated Nebulizer Study Protocol

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis

Nebulised Heparin in Patients With Severe COVID-19

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)